Incidence of and Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Thoracic Malignancies: A Prospective Multicenter Study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have fundamentally changed cancer treatment, but ICI-related pneumonitis (ICI-P) remains a major clinical concern. Although numerous studies have reported its incidence and risk factors, the retrospective nature of these studies makes accurate assessment difficult in a real-world clinical setting.

Patients and methods

This prospective multicenter observational study enrolled patients with advanced or recurrent thoracic malignancies treated with nivolumab, pembrolizumab, or atezolizumab. Thoracic high-resolution computed tomography (HRCT) examinations were performed at the start of ICI therapy and at the onset of ICI-P. The primary endpoint was ICI-P incidence. The secondary endpoints included evaluation of risk factors, with a f

SUBMITTER: Kitahara Y 

PROVIDER: S-EPMC13645426 | biostudies-literature | 2026 Sep

REPOSITORIES: biostudies-literature